Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.

Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeverbeke T, Mazieres B, Marcelli C, Leparc JM, Bertin P, Robin M, Sibilia J, Lafforgue P, Prati C, Combe B, Gottenberg JE; French Society of Rheumatology and the Club Rhumatismes et Inflammation.

J Rheumatol. 2012 Dec;39(12):2327-31. doi: 10.3899/jrheum.120201. Epub 2012 Aug 15.

PMID:
22896028
2.

Rituximab in psoriatic arthritis: an exploratory evaluation.

Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B, Machold KP, Graninger WB, Smolen JS.

Ann Rheum Dis. 2012 Nov;71(11):1868-71. doi: 10.1136/annrheumdis-2012-201897. Epub 2012 Jul 24.

PMID:
22833373
3.

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.

Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B; Club Rhumatismes et Inflammation (CRI/SFR).

Joint Bone Spine. 2007 Dec;74(6):638-46. Epub 2007 Nov 8.

PMID:
18065252
4.

Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.

Paramarta JE, De Rycke L, Ambarus CA, Tak PP, Baeten D.

Rheumatology (Oxford). 2013 Oct;52(10):1873-8. doi: 10.1093/rheumatology/ket239. Epub 2013 Jul 16.

PMID:
23861532
5.

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.

Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, Romero AB; MIRAR Study Group.

Ann Rheum Dis. 2012 Nov;71(11):1861-4. doi: 10.1136/annrheumdis-2012-201324. Epub 2012 Jun 26.

PMID:
22736086
6.

Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP.

Bodur H, Ataman S, Buğdaycı DS, Rezvani A, Nas K, Uzunca K, Emlakçıoğlu E, Karatepe AG, Durmuş B, Sezgin M, Ayhan F, Yazgan P, Duruöz T, Yener M, Gürgan A, Kırnap M, Cakar E, Altan L, Soydemir R, Capkın E, Tekeoğlu I, Aydın G, Günendi Z, Nacır B, Sallı A, Oztürk C, Memiş A, Turan Y, Kozanoğlu E, Sivrioğlu K; Türkiye Romatizma Araştırma ve Savaş Derneği [TRASD] (Turkish League Against Rheumatism) Ankylosing Spondylitis [AS] Study Group.

Rheumatol Int. 2012 Jan;32(1):169-76. doi: 10.1007/s00296-010-1599-7. Epub 2010 Aug 14.

PMID:
20711591
7.

Ethnic influence in clinical and functional measures of Brazilian patients with spondyloarthritis.

Skare TL, Bortoluzzo AB, Gonçalves CR, Braga da Silva JA, Ximenes AC, Bértolo MB, Ribeiro SL, Keiserman M, Menin R, Carneiro S, Azevedo VF, Vieira WP, Albuquerque EN, Bianchi WA, Bonfiglioli R, Campanholo C, Carvalho HM, Costa IP, Duarte AP, Gavi MB, Kohem CL, Leite NH, Lima SA, Meirelles ES, Pereira IA, Pinheiro MM, Polito E, Resende GG, Rocha FA, Santiago MB, Sauma Mde F, Sampaio-Barros PD.

J Rheumatol. 2012 Jan;39(1):141-7. doi: 10.3899/jrheum.110372. Epub 2011 Nov 1.

PMID:
22045839
8.

Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.

Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M.

Arthritis Care Res (Hoboken). 2013 Apr;65(4):648-52. doi: 10.1002/acr.21865.

9.
10.

Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.

Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Gottenberg JE, Mariette X.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1289-95.

PMID:
25299001
11.

Effect of enthesitis on 1505 Brazilian patients with spondyloarthritis.

Carneiro S, Bortoluzzo A, Gonçalves C, Silva JA, Ximenes AC, Bértolo M, Ribeiro SL, Keiserman M, Skare T, Menin R, Azevedo V, Vieira W, Albuquerque E, Bianchi W, Bonfiglioli R, Campanholo C, Carvalho HM, Costa Id, Duarte A, Kohem C, Leite N, Lima SA, Meirelles ES, Pereira IA, Pinheiro MM, Polito E, Resende GG, Rocha FA, Santiago MB, Sauma Mde F, Valim V, Sampaio-Barros PD.

J Rheumatol. 2013 Oct;40(10):1719-25. doi: 10.3899/jrheum.121145. Epub 2013 Jul 15.

PMID:
23858049
12.

Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis?

Mease PJ.

J Rheumatol. 2012 Dec;39(12):2235-7. doi: 10.3899/jrheum.121149. No abstract available.

PMID:
23204311
14.

Registry of the clinical characteristics of spondyloarthritis in a cohort of Egyptian population.

Tayel MY, Soliman E, El Baz WF, El Labaan A, Hamaad Y, Ahmed MH.

Rheumatol Int. 2012 Sep;32(9):2837-42. doi: 10.1007/s00296-011-2068-7. Epub 2011 Aug 31.

PMID:
21879376
15.

Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.

De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R; MIRA Study Group.

J Rheumatol. 2014 Sep;41(9):1761-5. doi: 10.3899/jrheum.131279. Epub 2014 Aug 15.

PMID:
25128506
16.

Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.

Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, Guigonis V, Pagnier A, Brochard K, Sibilia J, Gottenberg JE, Bodemer C; Club Rhumatismes et Inflammation.

J Rheumatol. 2011 Jul;38(7):1436-40. doi: 10.3899/jrheum.101321. Epub 2011 Jun 15.

PMID:
21677003
17.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
18.

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.

Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML.

Arthritis Rheum. 2011 Feb;63(2):382-90. doi: 10.1002/art.30117.

19.
20.

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.

Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML.

Ann Rheum Dis. 2010 Nov;69(11):2002-8. doi: 10.1136/ard.2009.124446. Epub 2010 May 28.

PMID:
20511613

Supplemental Content

Support Center